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ABSTRACT 
Rapid-dissolving solid drug dosage forms for application onto the oral cavity for the pediatric population seem to be very appropri ate, 
especially in preterm and term infants. The delivery of drugs via the oral mucosa offers easy application, prevents drug degradation by 
gastrointestinal fluids, avoids first-pass metabolism and potentially improves bioavailability. Granisetron hydrochloride (GSH) drug is used as 
antiemetic agent. Proposed work comprise of preformulation studies of Granisetron hydrochloride.  For that, physicochemical parameters were 
determined; like melting point of GSH was determined using melting point apparatus, Granisetron hydrochloride was scanned in the distilled 
water, Acid buffer, pH 1.2 and Phosphate buffer, pH 6.8. The IR spectrum of pure drug (GSH), Pullulan, METHO K3P, METHO E3P, METHO E15P 
and POLYOX WSR N10 were recorded in potassium bromide using Shimadzu FTIR – 8400S(CE). Solubility of Granisetron hydrochloride was 
determined using shake flask method. Standard Plot of Granisetron hydrochloride in distilled water, Acid buffer, pH 1.2 and Phosphate buffer, 
pH 6.8 were taken, all the parameter obtained were satisfactory, which will be used further for formulation of rapid dissolving film. 
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1. INTRODUCTION: 
The humble tablet, and its alter ego, the two piece hard 
gelatin capsule, remains at the forefront in terms of oral 
dosage form. Present situation that may be seen somewhat 
surprising considering the production, made over hundred 
year ago, suggesting that tablets have had their day, and will 
pass away to make room for something else. 
Thus, the appeal of these of dosage form remains high, 
providing a clear indication that choice may well be 
influenced by a need to: 
 Create a delivery system that is relatively simple and 
inexpensive to manufacture. 
 Provide a dosage form that is convenient, from the 
patient’s perspective, to use. 
 Utilize a technology that is relatively easy to adapt to 
changing need of the drug substance that will be 
incorporated into that particular dosage form. 
 Utilize an approach that is unlikely to add complexity 
during the regulatory approval process. 
1.1 Rapid (Fast) Dissolving Drug Delivery System 
Rapid-dissolving solid drug delivery system for application 
into the oral cavity for the pediatric population seem to be 
very appropriate, especially in preterm and term infants. 
The delivery of drugs via the oral mucosa offers easy 
application, prevents drug degradation by gastrointestinal 
fluids, avoids first-pass metabolism and potentially 
improves bioavailability with rapid absorption and fast 
onset of action. Drug absorption through membranes 
depends on the following:  
I. Drug concentration at the surface of the mucosa  
II. Vehicle for drug delivery  
III. Contact time with the mucosa  
IV. Constitution of mucosal tissue  
V. Degree of ionization of the drug 
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VI. pH of the absorption site 
VII. Size of the molecule and the relative lipid solubility  
These parameters have to be taken into account when 
formulating dosage forms for oral mucosal delivery. The 
drug concentration at the surface can be increased by 
varying the solubility of the drug. The drug partitioning can 
be influenced by environmental changes such as pH 
modifications. The permeability coefficient are often low, so 
the use of permeation enhancers is beneficial. The contact 
time at the mucosa may be prolonged by the use of 
mucoadhesive polymers such as chitosans, polyethylene 
glycol -tethered copolymers or alginates. 
1.2 Rapid Dissolving Dosage Form: 
Rapid-dissolving drug delivery systems have rapidly gained 
acceptance as an important new way of administering drugs. 
There are multiple fast-dissolving OTC and prescription 
products in the market worldwide, most of which have been 
launched in the past many years. There have also been 
significant increases in the number of new chemical entities 
under development using a rapid-dissolving drug delivery 
technology. 
A rapid-dissolving drug delivery system, in most cases, is a 
tablet that dissolves or disintegrates in the oral cavity 
without the need for water or chewing. Most rapid-
dissolving delivery system films must include substances to 
mask the taste of the active ingredient. This masked active 
ingredient is then swallowed by the patient's saliva along 
with the soluble and insoluble excipients. 
1.3 Classification of Rapid Dissolve Technology: 
For ease of description, rapid-dissolve technologies can 
be divided in to three broad groups: 
 Lyophilized systems, 
 Compressed tablet-based systems, 
 Oral thin film strips. 
 
 
2. EXPERIMENTAL WORK: 
Table 2.1 Profile of Granisetron Hydrochloride 
 
 
 
 
 
Parameters Description 
A. Analytical profile 
CAS number 107007-99-8 
Chemical structure 
 
Chemical formula C18H24N4O1·HCl 
Chemical name 
N-(9-methyl-9-azabicyclo [3.3.1] non-3-yl)-1-methyl-1H-indazole-3-carboxamide 
hydrochloride 
Molecular weight Average: 348.9g/mol 
pKa 9.4 
B. Pharmaceutical profile 
Appearance A whitish, crystalline powder 
Melting point 298°C 
Solubility Freely soluble in water, sparingly soluble in methylene chloride, slightly soluble in methanol 
Storage Store between 15ºC - 30ºC. Keep container closed tightly. Protect from light 
C. Pharmacodynamic profile: 
Mechanism of action 
Granisetron is a selective inhibitor of type 3 serotonergic (5-hydroxytryptamine, 5-HT3) 
receptors, with little or no affinity for other serotonin receptors. Granisetron possesses 
antiemetic activity due to its binding to 5-HT3 receptors, resulting in blockage of serotonin 
stimulation. 
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3. PREFORMULATION STUDIES 
Analyte Name: Granisetron hydrochloride (GSH) 
3.1 Melting Point: 
The melting point of GSH was determined using melting 
point apparatus.  
 
3.2 Scanning of the Drug (Granisetron hydrochloride): 
Granisetron hydrochloride was scanned in the following 
solvent and buffers- 
i) Distilled water 
ii) Acid buffer, pH 1.2 
iii) Phosphate buffer, pH 6.8 
i) Scanning of the drug in distilled water: 
50 mg of drug was dissolved in distilled water in 100 ml in 
volumetric flask, and volume was made to 100 ml with 
distilled water. 2 ml of this stock solution was further 
diluted to 100 ml to get concentration of 10µg/ml. This 
solution was scanned in UV-spectrophotometer. 
ii) Scanning of the drug in acid buffer, pH 1.2: 
50 mg of drug was dissolved in acid buffer, pH 1.2 in 100 ml 
in volumetric flask, and volume was made to 100 ml with 
same solvent. 2 ml of this stock solution was further diluted 
to 100 ml to get concentration of 10µg/ml. This solution was 
scanned in UV-spectrophotometer. 
iii) Scanning of the drug in phosphate buffer, pH 6.8: 
50 mg of drug was dissolved in phosphate buffer, pH 6.8 in 
100 ml in volumetric flask, and volume was made to 100 ml 
with same solvent. 2 ml of this stock solution was further 
diluted to 100 ml to get concentration of 10µg/ml. This 
solution was scanned in UV-spectrophotometer. 
3.3 Standard Plots: 
Standard plot of Granisetron HCl was prepared in following 
solvent and buffers- 
i) buffer, pH 6.8 
ii) i) Standard Distilled water 
iii) Acid buffer, pH 1.2 
Phosphate plot of Granisetron hydrochloride in distilled 
water 
50 mg of Granisetron hydrochloride was dissolved in 
distilled water and volume was made up to 100 ml by same 
solvent. This gave the concentration of 500 µg/ml (stock 
solution). 1, 2, 3, 4, 5 and 6 ml of this stock solution was 
further diluted to 100 ml to get different concentrations 
(µg/ml): 5, 10, 15, 20, 25 and 30. Absorbances were 
measured at the wave-length of 302 nm. 
ii) Standard plot of Granisetron hydrochloride in acid 
buffer, pH 1.2 
50 mg of Granisetron hydrochloride was dissolved in acid 
buffer, pH 1.2 and volume was made up to 100 ml by same 
solvent. This gave the concentration of 500 µg/ml (stock 
solution). 1, 2, 3, 4, 5 and 6 ml of this stock solution was 
further diluted to 100 ml to get different concentrations 
(µg/ml): 5, 10, 15, 20, 25 and 30. Absorbances were 
measured at the wave-length of 302 nm. 
iii) Standard plot of Granisetron hydrochloride in 
phosphate buffer, pH 6.8 
50 mg of Granisetron hydrochloride was dissolved in 
phosphate buffer, pH 6.8 and volume was made up to 100 ml 
by same solvent. This gave the concentration of 500 µg/ml 
(stock solution). 1, 2, 3, 4, 5 and 6 ml of this stock solution 
was further diluted to 100 ml to get different concentrations 
(µg/ml): 5, 10, 15, 20, 25 and 30. Absorbances were 
measured at the wave-length of 302 nm. 
3.4 Interpretation of IR Spectra: 
The IR spectrum of pure drug (GSH), Pullulan, METHO K3P, 
METHO E3P, METHO E15P and POLYOX WSR N10 were 
recorded in potassium bromide using Shimadzu FTIR – 8400 
S(CE). 
3.5 Solubility Studies:  
Solubility of Granisetron hydrochloride was determined 
using shake flask method. Solubility of Granisetron 
hydrochloride was determined in following solvents/ 
buffers: 
i) Distilled water 
ii) Acid buffer, pH 1.2 
iii) Phosphate buffer, pH 6.8 
4. RESULT AND DISCUSSION 
4.1 Preformulation Studies: Granisetron hydrochloride 
(GSH) 
4.2 Melting Point: 
The melting point of GSH was found to be 2880 C – 2920 C, 
which is same as documented (2910 C). 
4.3 Scanning of the Drug (Granisetron hydrochloride) 
Granisetron hydrochloride was scanned in the following 
solvent and buffers- 
iv) Distilled water 
v) Acid buffer, pH 1.2 
vi) Phosphate buffer, pH 6.8 
 
 
Fig.-1: UV spectrum of GSH in distilled water 
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Fig.-2: UV spectrum of GSH in acid buffer, pH 1.2 
 
 
Fig.-3: UV spectrum of GSH in phosphate buffer, pH 
6.8
Table 4.1: Summary of scanning of Granisetron hydrochloride in various solvents 
S. 
No. 
Amount of 
Granisetron 
hydrochloride 
(mg) 
Solvent used to 
make up 
volume 
Final 
volume 
(ml) 
Conc. of 
stock 
solution 
(µg/ml) 
Conc. of 
scanning 
solution 
(µg/ml) 
Scanning 
range 
(nm) 
Characteristic 
peak,  
max (nm) 
1 50 Distilled water 
 
1
0
0
 
500 
 
10 
 
2
0
0
 n
m
 –
 4
0
0
 n
m
 302 
2 50 
Acid Buffer, pH 
1.2 
500 
10 
 
302 
3 50 
Phosphate 
Buffer, pH 6.8 
500 
10 
 
302 
 
4.4 Standard Plots: 
Standard plot of Granisetron Hydrochloride was prepared in 
following solvent and buffers- 
i) Distilled water 
ii) Acid buffer, pH 1.2 
iii) Phosphate buffer, pH 6.8 
4.5 Standard Plot of Granisetron hydrochloride in 
distilled water: 
Concentration of stock solution = 500 µg/ml,  Drug = 
Granisetron hydrochloride 
Maximum wave-length (max) = 302 nm,  Solvent = 
distilled water 
 
Table 4.2: UV Absorbance of Granisetron hydrochloride 
in distilled water 
S. No. Conc. of Drug (µg/ml) 
Absorbance 
(Mean ± S.D.*) 
1 0 0.000±0.000 
2 5 0.152±0.006 
3 10 0.303±0.009 
4 15 0.456±0.006 
5 20 0.600±0.008 
6 25 0.753±0.005 
7 30 0.923±0.007 
* S. D. = Standard Deviation (n=3) 
 
 
(Fig.-4: Average UV-absorbance of Granisetron 
hydrochloride in distilled water±S.D. (n=3)) 
 
4.6 Standard Plot of Granisetron hydrochloride in Acid 
buffer, pH 1.2: 
Concentration of stock solution = 500 µg/ml, Drug = 
Granisetron hydrochloride 
Maximum wave-length (max) = 302 nm 
 Solvent = Acid buffer, pH 1.2 
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Table 4.3: UV Absorbance of Granisetron hydrochloride 
in acid buffer, pH 1.2 
S. No. 
Conc. of Drug 
(µg/ml) 
Absorbance 
(Mean ± S.D.*) 
1 0 0.000±0.000 
2 5 0.1920.007 
3 10 0.3440.006 
4 15 0.5090.006 
5 20 0.6770.007 
6 25 0.8510.007 
7 30 1.0200.008 
* S. D. = Standard Deviation (n=3) 
 
 
(Fig.-5: Average UV-absorbance of Granisetron 
hydrochloride in acid buffer pH, 1.2±S.D. (n=3)) 
 
4.7 Standard Plot of Granisetron hydrochloride in 
Phosphate buffer, pH6.8: 
Concentration of stock solution = 500 µg/ml, Drug = 
Granisetron hydrochloride 
Maximum wave-length (max) = 302 nm, 
 Solvent = Phosphate buffer, pH 6.8 
Table 4.4: UV Absorbance of Granisetron hydrochloride 
in phosphate buffer, pH 6.8 
S. No. 
Conc. of Drug 
(µg/ml) 
Absorbance 
(Mean ± S.D.*) 
1 0 0.000±0.000 
2 5 0.177±0.006 
3 10 0.348±0.006 
4 15 0.508±0.007 
5 20 0.678±0.007 
6 25 0.835±0.008 
7 30 1.019±0.008 
* S. D. = Standard Deviation (n=3) 
 
 
(Fig.-6: Average UV-absorbance of Granisetron 
hydrochloride in phosphate buffer pH, 6.8±S.D. (n=3)) 
5. CONCLUSION: 
Granisetron hydrochloride is used as an antiemetic agent. 
The drug was scanned in the distilled water, Acid buffer, pH 
1.2 and Phosphate buffer, pH 6.8. The IR spectrum of pure 
drug (GSH), Pullulan, were recorded in potassium bromide 
using Shimadzu FTIR – 8400 S(CE). Solubility of Granisetron 
hydrochloride was determined using shake flask method. 
Standard Plot of Granisetron hydrochloride were prepared 
in distilled water, Acid buffer, pH 1.2 and Phosphate buffer, 
pH 6.8. all the parameter obtained were satisfactory, which 
will be used further for formulation of rapid dissolving film. 
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